TOP TEN perturbations for 38489_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38489_at
Selected probe(set): 205014_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38489_at (205014_at) across 6674 perturbations tested by GENEVESTIGATOR:
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):6.2973537Number of Samples:3 / 8
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). | |
| Control | esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted). |
diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)
Relative Expression (log2-ratio):-6.019788Number of Samples:34 / 19
| Experimental | diabetes type 2 study 27 (LCM) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year. | |
| Control | diabetes type 2 study 27 (enzymatic) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies. |
esophageal adenocarcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-5.9304686Number of Samples:20 / 18
| Experimental | esophageal adenocarcinoma study 1 |
| Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Relative Expression (log2-ratio):5.836443Number of Samples:2 / 9
| Experimental | expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin. | |
| Control | expO skin cancer study 1 (malignant melanoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-5.177595Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
TGF-β study 12 / untreated NCI-H358 cell sample
Relative Expression (log2-ratio):-5.090955Number of Samples:3 / 3
| Experimental | TGF-β study 12 |
| NCI-H358 cells were cultured for 2-3 weeks in the presence of 2ng/ml of TGF-β, to induce epithelial-mesenchymal transition (EMT). 24 hours prior analysis cells were re-seeded without TGF-β. | |
| Control | untreated NCI-H358 cell sample |
| NCI-H358 cells grown in standard media. |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):5.061187Number of Samples:43 / 2
| Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):4.820388Number of Samples:43 / 4
| Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Relative Expression (log2-ratio):4.619074Number of Samples:43 / 4
| Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). |
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-4.2579517Number of Samples:2 / 10
| Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |